U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C12H10O4
Molecular Weight 218.2054
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACIFRAN

SMILES

CC1(OC(=CC1=O)C(O)=O)C2=CC=CC=C2

InChI

InChIKey=DFDGRKNOFOJBAJ-UHFFFAOYSA-N
InChI=1S/C12H10O4/c1-12(8-5-3-2-4-6-8)10(13)7-9(16-12)11(14)15/h2-7H,1H3,(H,14,15)

HIDE SMILES / InChI

Molecular Formula C12H10O4
Molecular Weight 218.2054
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16389067 | http://adisinsight.springer.com/drugs/800000311 | https://www.ncbi.nlm.nih.gov/pubmed/6818976 | https://www.ncbi.nlm.nih.gov/pubmed/3314798

Acifran (AY-25,712), an uncommercialized Ayerst compound exerting lipid-lowering activity in vivo, has been shown to also elicit similar effects as niacin in preliminary clinical testing and has been shown to bind to both high affinity (HM74A; GPR109A) and low affinity (HM74; GPR109B) niacin receptors. The EC50 values of the separated acifran enantiomers for the GPR109a and 109b receptors showed that, as with acifran itself, the (+)-enantiomers were essentially twice as active as the racemic mixtures, whereas the activity of the (-)-enantiomers was more variable and highly dependent on purity. S-enantiomer of acifran is the active principle. All of the activity of racemic acifran could be attributed to the (S)-enantiomer, and hence, from this precedent, (+)-enantiomers would be assigned to the S-configuration. However, the absolute configuration was not confirmed experimentally.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.22 μg/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4.26 μg/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.4 μg × h/mL
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
15.6 μg × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.7 h
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
1.4 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
12.2%
200 mg 2 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACIFRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
300 mg 3 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 3 times / day
Route: oral
Route: multiple
Dose: 300 mg, 3 times / day
Sources: Page: p.315
unhealthy, ADULT
n = 13
Health Status: unhealthy
Condition: hyperlipoproteinemia
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 13
Sources: Page: p.315
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
(D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G.
2005 Jul 22
Langerhans cells release prostaglandin D2 in response to nicotinic acid.
2006 Dec
International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B).
2011 Jun
Patents

Patents

Sample Use Guides

neither 1 nor 10 mg/kg (R)-acifran ((-)-enantiomers would be assigned to the R-configuration) decrease serum triglycerides in fructose-fed rats
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 15:57:52 GMT 2023
Edited
by admin
on Sat Dec 16 15:57:52 GMT 2023
Record UNII
B1X701S0MV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACIFRAN
INN   MART.   MI   USAN  
USAN   INN  
Official Name English
acifran [INN]
Common Name English
REDUCTOL
Brand Name English
AY-25712
Code English
2-FURANCARBOXYLIC ACID, 4,5-DIHYDRO-5-METHYL-4-OXO-5-PHENYL-
Systematic Name English
AY-25,712
Code English
(±)-4,5-DIHYDRO-5-METHYL-4-OXO-5-PHENYL-2-FUROIC ACID
Systematic Name English
2-FURANCARBOXYLIC ACID, 4,5-DIHYDRO-5-METHYL-4-OXO-5-PHENYL-, (±)-
Common Name English
ACIFRAN [MART.]
Common Name English
ACIFRANUM
Common Name English
ACIFRAN [MI]
Common Name English
ACIFRAN [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C98151
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL278488
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
EVMPD
SUB05236MIG
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID9045685
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
USAN
S-52
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
WIKIPEDIA
Acifran
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
INN
5515
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
FDA UNII
B1X701S0MV
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
CAS
72420-38-3
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
PUBCHEM
51576
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
SMS_ID
100000084622
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
NCI_THESAURUS
C81534
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY
MERCK INDEX
m999
Created by admin on Sat Dec 16 15:57:53 GMT 2023 , Edited by admin on Sat Dec 16 15:57:53 GMT 2023
PRIMARY Merck Index
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY